STATEMENT ON NEW DRUG COMPANY LAWSUITS TARGETING THE 340B PROGRAM
WASHINGTON, D.C.— The pharmaceutical companies Eli Lilly, AstraZeneca, and Sanofi yesterday filed separate lawsuits in federal court challenging their legal obligations to provide 340B drug pricing program discounts on drugs dispensed at community pharmacies. The following statement is attributed to 340B Health President and CEO Maureen Testoni:
“It is disappointing, but not surprising, that these huge, for-profit drug companies are continuing to attack the nation’s health care safety net when it already is under great duress. By refusing to comply with the law and withholding mandatory 340B discounts, these manufacturers are depriving safety-net hospitals of the vital resources they require to care for patients in need amid the COVID-19 pandemic. Their illegal actions will prolong the pain for providers and patients. The Dec. 30 advisory opinion from the Department of Health and Human Services is crystal clear. These manufacturer actions are in direct violation of the law and must stop. It is long past time for drug companies to stop unilaterally cutting 340B.”
Contact: Richard Sorian at email@example.com or 202-536-2285.